KING OF PRUSSIA, Pa.
,
Jan. 5
/PRNewswire/ — Prism Pharmaceuticals
announced today that the U.S. Food & Drug Administration (FDA) has approved
the new drug application (NDA) for NEXTERONE(R) (amiodarone HCl) Injection, a
novel, patent-protected, cosolvent free formulation of the antiarrhythmic
agent Amiodarone IV, originally marketed in the US by Wyeth as Cordarone(R)
Intravenous. NEXTERONE is indicated for the treatment and prophylaxis Read the rest of this entry »

Prism Pharmaceuticals Receives FDA Approval of NEXTERONE(R) for
Life-Threatening Ventricular Fibrillation and Ventricular Tachycardia
-Novel Formulation Addresses Limitations of Amiodarone IV-

KING OF PRUSSIA, Pa., Jan. 5 /PRNewswire/ — Prism Pharmaceuticals
announced today that the U.S. Food & Drug Administration (FDA) has approved
the new drug application (NDA) for NEXTERONE(R) (amiodarone HCl) Injection, a
novel, patent-protected, cosolvent free Read the rest of this entry »